O63 HPV E6/E7 mRNA and MCM2/TOP2a testing in cervical cancer screening: results from a multicentre Canadian study

Ratnam, Samuel; Fontaine, Dorrie K.; Coutlée, François; Bentley, J.; Escott, Nicholas; Ghatage, Prafull; Bartellas, Elias; Kum, Nick; Giede, Christopher; Lear, Adrian

doi:10.1016/s0924-8579(09)70210-9

Cited by 2 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, “concern” with these items was low. For flow and timing, six studies did not cite the interval between the index and referenced tests [12, 24, 25, 35, 37, 75], and in one, the interval was considered inadequate because it was from a cohort that did not show separate baseline and follow-up results [27]. In cohort studies, we considered the results of the baseline whenever possible.…”

Section: Resultsmentioning

confidence: 99%

“…Some studies applied two or more assays to the same sample, making it possible to compare them. In the outcome CIN1- vs. CIN2+, comparing Aptima to Hybrid Capture 2 (HC2, Qiagen, Gaithesburg, MD, USA), a DNA hrHPV test, fourteen studies were available [8, 12–14, 19, 20, 25–29, 31, 32, 35]. The pooled sensitivity identified was 93.9% (95%CI 92.8-94.8) and 94.3% (95%CI 93.3-95.2), pooled specificity of 61.5% (95%CI 60.6-62.7) and 51.3% (95%CI 50.2-52.4), the DOR was 15.96 (95%CI 10.14-25.17) and 12.55 (95%CI 92.33-17.07), and the AUC was 0.90 (0.80-1) and 0.91 (0.88-0.95), respectively, for Aptima and Hybrid Capture 2 (Table 3).…”

Section: Resultsmentioning

confidence: 99%

“… ∗ Excluding CIN2 from analysis. CIN: cervical intraepithelial neoplasia; CI: Confidence interval; DOR: diagnostic odds ratio; AUC: area under the curve; TP: true positive; FP: false positive; FN: false negative; TN: true negative.Included studies CIN1- vs. CIN2+: Aptima [8–35]; NucliSens EasyQ HPV [36–46]; OncoTect [41, 47–51]; PreTect HPV Proofer [14, 23, 25, 31, 52–61]; Quantivirus [45, 62–65]. CIN1- vs. CIN3+: Aptima [8–15, 18–22, 24, 26–31, 33–35]; NucliSens EasyQ HPV [36, 37, 41, 46]; OncoTect [41, 47–50]; PreTect HPV Proofer [14, 31, 59–61]; Quantivirus [62–64].…”

Section: Figurementioning

confidence: 99%

“…Included studies CIN1- vs. CIN2+: Aptima [8–35]; NucliSens EasyQ HPV [36–46]; OncoTect [41, 47–51]; PreTect HPV Proofer [14, 23, 25, 31, 52–61]; Quantivirus [45, 62–65]. …”

Section: Figurementioning

confidence: 99%

See 3 more Smart Citations

Accuracy of mRNA HPV Tests for Triage of Precursor Lesions and Cervical Cancer: A Systematic Review and Meta-Analysis

Macedo¹,

Gonçalves²,

Bavaresco³

et al. 2019

Journal of Oncology

View full text Add to dashboard Cite

Objective. This systematic review evaluates the accuracy of the mRNA HPV biomarker in cervical smears to identify cervical intraepithelial neoplasia (CIN) 2 or 3 and cervical cancer. Data Source. Eligible studies were identified by performing a search of electronic databases on Medline via Pubmed, Lilacs, Cochrane Library, Embase, and Grey literature for papers published between January 1990 and June 2018. Study Eligibility Criteria. As no randomized studies were identified, this review focuses on observational studies in which the mRNA HPV diagnostic test was compared to a histopathology reference standard. We analyzed studies that included women screened for cervical cancer using mRNA HPV. Study Appraisal and Synthesis Methods. After screening, 61 studies including 29,674 patients met the inclusion criteria and were analyzed. Dichotomization was performed by defining CIN2 or worse (CIN2+) versus CIN1, HPV infection, and normal (CIN 1-). The analysis was discriminated by the following tests: Aptima, PreTect HPV Profeer, NucliSens EasyQ HPV, OncoTect, and Quantivirus. Results. Analyzing by technique, Aptima, with 28 studies, exhibited superior performance, showing for the outcomes CIN2+ and CIN3+ an AUC of 0.88 (0.82-0.95) and 0.91 (0.84-0.99), a pooled sensitivity of 92.8% (95%CI 91.9-93.7) and 95.6% (95%CI 94.5-96.5), and a pooled specificity of 60.5% (95%CI 59.8-61.3) and 61.9% (95%CI 61.1-62.7), respectively. Conclusion. This study supports the current hypothesis that the mRNA HPV assay is an adequate tool for secondary cervical cancer screening.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Figurementioning

confidence: 99%

“…Included studies CIN1- vs. CIN2+: Aptima [8–35]; NucliSens EasyQ HPV [36–46]; OncoTect [41, 47–51]; PreTect HPV Proofer [14, 23, 25, 31, 52–61]; Quantivirus [45, 62–65]. …”

Section: Figurementioning

confidence: 99%

See 2 more Smart Citations

Accuracy of mRNA HPV Tests for Triage of Precursor Lesions and Cervical Cancer: A Systematic Review and Meta-Analysis

Macedo¹,

Gonçalves²,

Bavaresco³

et al. 2019

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…In CC, the expression of TOP2A is related to the clinicopathological parameters of patients and is correlated with their prognosis. 41 In this study, we found a drug-gene interaction between TOP2A and 12 drugs in CC tissues.…”

Section: Discussionmentioning

confidence: 52%

Longitudinal Analysis of Gene Expression Changes During Cervical Carcinogenesis Reveals Potential Therapeutic Targets

Wei

2020

Evol Bioinform Online

View full text Add to dashboard Cite

Despite advances in the treatment of cervical cancer (CC), the prognosis of patients with CC remains to be improved. This study aimed to explore candidate gene targets for CC. CC datasets were downloaded from the Gene Expression Omnibus database. Genes with similar expression trends in varying steps of CC development were clustered using Short Time-series Expression Miner (STEM) software. Gene functions were then analyzed using the Gene Ontology (GO) database and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Protein interactions among genes of interest were predicted, followed by drug-target genes and prognosis-associated genes. The expressions of the predicted genes were determined using real-time quantitative polymerase chain reaction (RT-qPCR) and Western blotting. Red and green profiles with upward and downward gene expressions, respectively, were screened using STEM software. Genes with increased expression were significantly enriched in DNA replication, cell-cycle-related biological processes, and the p53 signaling pathway. Based on the predicted results of the Drug-Gene Interaction database, 17 drug-gene interaction pairs, including 3 red profile genes (TOP2A, RRM2, and POLA1) and 16 drugs, were obtained. The Cancer Genome Atlas data analysis showed that high POLA1 expression was significantly correlated with prolonged survival, indicating that POLA1 is protective against CC. RT-qPCR and Western blotting showed that the expressions of TOP2A, RRM2, and POLA1 gradually increased in the multistep process of CC. TOP2A, RRM2, and POLA1 may be targets for the treatment of CC. However, many studies are needed to validate our findings.

show abstract

O63 HPV E6/E7 mRNA and MCM2/TOP2a testing in cervical cancer screening: results from a multicentre Canadian study

Cited by 2 publications

References 0 publications

Accuracy of mRNA HPV Tests for Triage of Precursor Lesions and Cervical Cancer: A Systematic Review and Meta-Analysis

Accuracy of mRNA HPV Tests for Triage of Precursor Lesions and Cervical Cancer: A Systematic Review and Meta-Analysis

Longitudinal Analysis of Gene Expression Changes During Cervical Carcinogenesis Reveals Potential Therapeutic Targets

Contact Info

Product

Resources

About